Qualyst, which provides technologies for the drug discovery and development marketplace, has formed a Scientific Advisory Board with seven members.

The chair of the board is Kim Brouwer, a founder of Qualyst and professor at the University of North Carolina at Chapel Hill School of Pharmacy. Brower also serves as the company’s vice president of research and development.

Joining Brouwer on the board from the UNC-CH School of Pharmacy is professor Gary Pollack, who is also a founder of RTP-based Qualyst.

Other members of the board include Ronald Borchardt, a professor of pharmaceutical chemistry at the University of Kansas. Borchardt is the author or co-author of some 400 scientific publications and 350 abstracts. His research focuses on drug design and drug delivery. Borchardt is also a member of the Qualyst Board of Directors.

Richard Kim is an associate professor in the department of medicine and pharmacology at Vanderbilt University. Kim’s research focuses on the factors that contribute to differences in how individuals metabolize and respond to drugs.

Anthony Lu is an adjunct professor (in residence) at the Susan Lehman Cullman Laboratory for Cancer Research in the department of chemical biology at the Ernest Mario School of Pharmacy at Rutgers University. Lu retired as executive director of Merck in 1999, having been employed by Roche and Merck for the past 30 years. He has authored or co-authored more than 230 publications in his fields of interest, including practical applications of drug metabolizing enzymes.

Gerald Miwa is VP of drug metabolism and pharmacokinetics at Millennium Pharmaceuticals. Previously, Miwa served in the same role at the DuPont Pharmaceuticals Co. His interests are in the application of drug metabolism and pharmacokinetics to the optimization of drug candidates for development and to the elucidation of the chemical and biochemical basis for drug toxicities.

“The members of this advisory board are all leaders in their respective fields of study,” said Scott Neuville, Qualyst president and CEO. “Collectively, their scientific expertise will assist Qualyst in its mission to be the world leader in providing novel ADMET technologies to the life sciences industry–.”

Qualyst: www.qualyst.com